Boston Scientific (BSX) will buy Penumbra (PEN) for $14.5 billion, the companies said Thursday. The deal expands Boston Scientific’s cardiovascular reach and sent Penumbra stock to a record high.
At a Glance
- Boston Scientific will pay $374 per share, a 20% premium to Penumbra’s prior close
- The transaction values Penumbra at nine times its projected 2026 sales
- Penumbra shares jumped to an all-time high on the news
- Why it matters: The acquisition strengthens Boston Scientific’s position in fast-growing stroke and clot-removal markets
The acquisition price of $374 per share represents a 20% premium to Penumbra’s last closing price before the announcement. William Blair analyst Brandon Vazquez noted the deal implies a valuation of nine times Penumbra’s estimated 2026 sales.
Penumbra’s stock surged to a record high following the announcement, reflecting investor confidence in the strategic fit between the two medical-device makers.
Boston Scientific said the purchase will broaden its portfolio of products that treat blood clots and stroke, areas where Penumbra has built a strong franchise.
The deal is expected to close in the first half of 2025, pending regulatory and shareholder approvals.
